Micropaque Suspensie (Barium Sulfate)

Barium sulfate contains a high atomic number element that absorbs X‑rays. When the suspension coats the gastrointestinal lining, it creates a dense, white layer on radiographs, providing contrast between the lumen and surrounding tissues and allowing detailed imaging of the GI tract.

The appropriate dose of Micropaque Suspensie is determined by the prescribing physician based on the specific imaging study, patient age, weight, and clinical requirements. Dosing is individualized and should follow the healthcare professional’s instructions.

Safety of Micropaque Suspensie in pregnancy or lactation has not been established. It should be used only when the diagnostic benefit justifies any potential risk to the fetus or infant, and after careful evaluation by the treating physician.

To order Micropaque Suspensie, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Micropaque Suspensie (barium sulfate) provides superior coating of the gastrointestinal lumen and produces high‑contrast images without the risk of iodine‑related allergic reactions. However, it is limited to GI tract studies, whereas iodine‑based agents can be used for vascular and soft‑tissue imaging.

Micropaque Suspensie should be stored at ambient temperature, preferably below 25 °C. Keep the suspension in its original container, protect it from moisture and direct sunlight, and ensure the seal remains intact to maintain product stability.

The suspension can be given orally as a drink or introduced rectally via an enema, depending on the specific imaging protocol. Administration is performed by trained healthcare personnel in a radiology or endoscopy suite following standard procedural guidelines.

Serious risks, though rare, include bowel obstruction, severe allergic reactions such as anaphylaxis, and peritonitis. Immediate medical attention is required if patients experience intense abdominal pain, swelling, difficulty breathing, or signs of systemic allergic response after administration.

Patients with known gastrointestinal perforation, severe bowel obstruction, or a documented hypersensitivity to barium sulfate should not receive Micropaque Suspensie. Additionally, use is contraindicated in individuals where alternative imaging methods are safer or more appropriate.